Drugmakers call off animal-health deal, possible asset sale

Back to TopCommentsE-mailPrintBookmark and Share

Drugmakers Merck & Co. and Sanofi-Aventis SA said Tuesday they have abandoned plans to combine their animal-health businesses after wrestling with regulators for a year over potential divestitures.

Indianapolis-based Eli Lilly and Co. was among a list of possible suitors for about $1 billion in assets the two companies considered selling to resolve antitrust concerns.

Lilly has been trying to grow its animal-health business through acquisitions in order to build up revenue expected to be lost late this year when its bestselling human drug Zyprexa faces competition from cheaper generic copies.

Earlier this month, Lilly’s Elanco animal-health division agreed to acquire Jannsen Animal Health, a subsidiary of New Jersey-based Johnson & Johnson. Financial terms of the deal were not disclosed.

Merck and Sanofi’s decision ends a plan to create the world’s biggest maker of medicines for livestock and pets. The drugmakers were to have been equal owners of the joint venture announced last March. The units had combined sales of $5.5 billion last year.

“It was clear from the beginning that there would be problems from the regulatory side,” said Oliver Kaemmerer, an analyst with WestLB AG in London. Kaemmerer said he believes Merck and Sanofi when they say they won’t sell their animal- health assets, but “never say never.”

For now, the companies will keep the Merial and Intervet units separate at no penalty to either side. Merck, based in Whitehouse Station, N.J., and Paris-based Sanofi remain committed to animal health, they said in a statement.

Merial’s products include a bird-flu vaccine for poultry and Frontline, the best-selling flea spray for pets, while Intervet makes a device to vaccinate pigs without a needle and the Safe-Guard treatment to deworm dogs.

“The companies are discontinuing their agreement primarily because of the increasing complexity of implementing the proposed transaction, both in terms of the nature and extent of the anticipated divestitures and the length of time necessary for the worldwide regulatory review process,” Merck and Sanofi said in the statement.

The two companies had hired Morgan Stanley to arrange the sale of assets valued at about $1 billion to resolve antitrust concerns, two sources with knowledge of the matter said in October. Prospective buyers may have included Lilly, Pfizer Inc., Bayer AG, Boehringer Ingelheim GmbH and Novartis AG, the sources said.

Potential buyers showed a lot of interest in the assets, Sanofi Chief Executive Officer Chris Viehbacher said on a Feb. 9 conference call.

Sanofi and Merck operated Merial as a joint venture for more than a decade. Sanofi bought out its partner’s stake for $4 billion in 2009, removing an antitrust obstacle to Merck’s acquisition of Schering-Plough Corp.

Merck and Sanofi agreed a year ago form a new partnership that combined Merial and the Intervet veterinary unit that Merck got in the Schering-Plough purchase.

Viehbacher sought to expand in veterinary products in part because the business wasn’t as vulnerable as prescription drugs to competition from generic products. Growing demand for food also helped lift sales of products for farm animals, and rising incomes were leading to increased pet ownership, he said.

“This is one of those sweet spots that provide sustainability of sales and earnings growth,” Viehbacher said on the Feb. 9 call.


Post a comment to this story

We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
You are legally responsible for what you post and your anonymity is not guaranteed.
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
Subscribe to IBJ
  1. With Pence running the ship good luck with a new government building on the site. He does everything on the cheap except unnecessary roads line a new beltway( like we need that). Things like state of the art office buildings and light rail will never be seen as an asset to these types. They don't get that these are the things that help a city prosper.

  2. Does the $100,000,000,000 include salaries for members of Congress?

  3. "But that doesn't change how the piece plays to most of the people who will see it." If it stands out so little during the day as you seem to suggest maybe most of the people who actually see it will be those present when it is dark enough to experience its full effects.

  4. That's the mentality of most retail marketers. In this case Leo was asked to build the brand. HHG then had a bad sales quarter and rather than stay the course, now want to go back to the schlock that Zimmerman provides (at a considerable cut in price.) And while HHG salesmen are, by far, the pushiest salesmen I have ever experienced, I believe they are NOT paid on commission. But that doesn't mean they aren't trained to be aggressive.

  5. The reason HHG's sales team hits you from the moment you walk through the door is the same reason car salesmen do the same thing: Commission. HHG's folks are paid by commission they and need to hit sales targets or get cut, while BB does not. The sales figures are aggressive, so turnover rate is high. Electronics are the largest commission earners along with non-needed warranties, service plans etc, known in the industry as 'cheese'. The wholesale base price is listed on the cryptic price tag in the string of numbers near the bar code. Know how to decipher it and you get things at cost, with little to no commission to the sales persons. Whether or not this is fair, is more of a moral question than a financial one.